Etelcalcetide Injection (Parsabiv)

Covered: Parsabiv (etelcalcetide) is authorized only for adult CKD patients on hemodialysis with secondary hyperparathyroidism and is not approved for off‑label uses or concurrent use with cinacalcet. Key requirements: patient must be on current hemodialysis, have corrected serum calcium ≥7.5 mg/dL with no signs of hypocalcemia, PTH ≥300 pg/mL for initial approval (≥100 pg/mL for reauthorization), documented dosing per policy (IV 2.5–15 mg three times weekly, start 5 mg), and approvals are limited to 12 months with required supporting documentation.

"Reauthorization requires a parathyroid hormone (PTH) level of 100 pg/mL or greater."

Sign up to see full coverage criteria, indications, and limitations.